苯达莫司汀-利妥昔单抗治疗后继发的致命性 COVID-19 突破感染病例。
A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy.
机构信息
National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine, Tokyo, Japan.
出版信息
Int J Infect Dis. 2022 Aug;121:85-88. doi: 10.1016/j.ijid.2022.04.058. Epub 2022 Apr 30.
Abstract
Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serologic study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately.
摘要
尽管信使核糖核酸疫苗对 SARS-CoV-2 感染具有显著效果，但血液系统恶性肿瘤患者仍易感染该病毒。在此，我们报告了一例黏膜相关淋巴组织淋巴瘤患者在完成一年前苯达莫司汀-利妥昔单抗（BR）治疗后突破性感染 SARS-CoV-2 Delta 变异株的致死病例。血清学研究显示疫苗反应受损和感染后病毒载量持续高。BR 治疗似乎诱导了免疫逃逸。应立即明确针对此类脆弱患者的预防和治疗策略。
相似文献
1
A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy.苯达莫司汀-利妥昔单抗治疗后继发的致命性 COVID-19 突破感染病例。
Int J Infect Dis. 2022 Aug;121:85-88. doi: 10.1016/j.ijid.2022.04.058. Epub 2022 Apr 30.
2
Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report.苯达莫司汀和利妥昔单抗治疗后严重急性呼吸综合征冠状病毒 2 的持续病毒脱落：一例报告。
J Infect Chemother. 2022 Jun;28(6):810-813. doi: 10.1016/j.jiac.2022.01.014. Epub 2022 Jan 31.
3
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.两例滤泡性淋巴瘤患者在接受苯达莫司汀和奥滨尤妥珠单抗或利妥昔单抗治疗后出现持续性 SARS-CoV-2 感染和多次临床复发。
Infection. 2023 Oct;51(5):1577-1581. doi: 10.1007/s15010-023-02039-2. Epub 2023 Apr 19.
4
Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy.别嘌醇-利妥昔单抗-苯达莫司汀治疗引发的致命性史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症
J Oncol Pharm Pract. 2015 Oct;21(5):388-92. doi: 10.1177/1078155214533368. Epub 2014 Jul 7.
5
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.一线采用苯达莫司汀-利妥昔单抗治疗滤泡淋巴瘤后维持利妥昔单抗或观察。
Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21.
6
Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.苯达莫司汀暴露对滤泡性淋巴瘤患者接受苯达莫司汀与利妥昔单抗联合治疗后淋巴细胞减少风险的临床影响：一项单机构回顾性研究
Ann Hematol. 2022 Jan;101(1):209-211. doi: 10.1007/s00277-020-04388-6. Epub 2021 Jan 3.
7
Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.免疫功能低下患者在接受奥滨尤妥珠单抗联合苯达莫司汀治疗滤泡性淋巴瘤后出现持续 COVID-19。
Intern Med. 2022 Aug 15;61(16):2523-2526. doi: 10.2169/internalmedicine.9136-21. Epub 2022 May 31.
8
Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.非霍奇金淋巴瘤患者中基于苯达莫司汀化疗相关皮肤毒性的危险因素
Biol Pharm Bull. 2020 Oct 1;43(10):1577-1582. doi: 10.1248/bpb.b20-00428. Epub 2020 Aug 14.
9
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.一项在未经治疗的滤泡性淋巴瘤患者中进行的苯达莫司汀/利妥昔单抗联合硼替佐米诱导或来那度胺维持的三臂随机 II 期研究：ECOG-ACRIN E2408。
Clin Cancer Res. 2020 Sep 1;26(17):4468-4477. doi: 10.1158/1078-0432.CCR-20-1345. Epub 2020 Jun 12.
10
Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab.血清免疫球蛋白 G 可作为滤泡性淋巴瘤患者接受苯达莫司汀联合利妥昔单抗化疗后感染的鉴别诊断标志物。
Hematology. 2022 Dec;27(1):384-395. doi: 10.1080/16078454.2022.2051863.
引用本文的文献
1
Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study.COVID-19 mRNA 疫苗加强针的初步疗效及随后在 B 细胞非霍奇金淋巴瘤患者中奥密克戎变异株突破性感染的研究：一项单中心队列研究。
Viruses. 2024 Feb 21;16(3):328. doi: 10.3390/v16030328.
2
High diagnostic accuracy of quantitative SARS-CoV-2 spike-binding-IgG assay and correlation with viral neutralizing activity.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突结合免疫球蛋白G（IgG）定量检测具有高度诊断准确性及其与病毒中和活性的相关性
Heliyon. 2024 Jan 13;10(2):e24513. doi: 10.1016/j.heliyon.2024.e24513. eCollection 2024 Jan 30.
3
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.抗 CD20 抗体和苯达莫司汀可减弱 B 细胞非霍奇金淋巴瘤患者对 COVID-19 疫苗的体液免疫反应。
Ann Hematol. 2023 Jun;102(6):1421-1431. doi: 10.1007/s00277-023-05204-7. Epub 2023 Apr 12.
本文引用的文献
1
CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma.在B细胞淋巴瘤患者中，CD19阳性淋巴细胞计数对于接种疫苗后抗SARS-CoV-2 IgG的获得至关重要。
Blood Adv. 2022 Jun 14;6(11):3230-3233. doi: 10.1182/bloodadvances.2021006302.
2
Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report.巴瑞替尼成功治疗一名因抗CD20单克隆抗体治疗导致严重B细胞发育不全的新冠长期感染者：病例报告
Respir Med Case Rep. 2021;34:101560. doi: 10.1016/j.rmcr.2021.101560. Epub 2021 Nov 29.
3
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.三剂 BNT162b2 mRNA COVID-19 疫苗在标准两剂接种失败的 CLL 患者中的疗效。
Blood. 2022 Feb 3;139(5):678-685. doi: 10.1182/blood.2021014085.
4
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.BNT162b2 疫苗接种者中和/SARS-CoV-2-S1 结合抗体反应与不良反应和免疫动力学的相关性。
Sci Rep. 2021 Nov 24;11(1):22848. doi: 10.1038/s41598-021-01930-y.
5
Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.高中和抗体滴度的 COVID-19 恢复期血浆能有效阻断 SARS-CoV-2 复制并减轻叙利亚仓鼠的肺炎症状。
J Virol. 2022 Feb 23;96(4):e0155121. doi: 10.1128/JVI.01551-21. Epub 2021 Nov 24.
6
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.血液系统恶性肿瘤患者对2019冠状病毒病信使核糖核酸疫苗的反应欠佳：在后口罩时代需要保持警惕
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353. doi: 10.1093/ofid/ofab353. eCollection 2021 Jul.
7
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.血液系统恶性肿瘤患者对SARS-CoV-2疫苗的抗体反应。
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
8
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
9
Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail.在一位 B 细胞耗竭相关的持续性（B-DEAP）COVID 患者中，使用 REGEN-COV 抗刺突单克隆抗体鸡尾酒成功清除了 300 天的 SARS-CoV-2 感染。
Viruses. 2021 Jun 23;13(7):1202. doi: 10.3390/v13071202.
10
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
Zotero 插件